How many drugs treat CMV Retinitis in AIDS Patients?

Drug Landscape tracks 5 marketed treatments for CMV Retinitis in AIDS Patients (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/cmv-retinitis-in-aids-patients.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CMV Retinitis in AIDS Patients — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CMV Retinitis in AIDS Patients (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating CMV Retinitis in AIDS Patients, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Valcyte	VALGANCICLOVIR	Cheplapharm	Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor		2001-01-01
Vistide	CIDOFOVIR	Gilead Sciences	cidofovir		1996-01-01
Foscavir	FOSCARNET	Clinigen Hlthcare	Pyrophosphate Analog DNA Polymerase Inhibitor		1991-01-01
Cytovene	GANCICLOVIR	Roche Palo	Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor	Metabotropic glutamate receptor 1	1989-01-01
Vistide	Vistide	Gustave Roussy, Cancer Campus, Grand Paris		DNA polymerase catalytic subunit

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Cheplapharm · 1 drug in CMV Retinitis in AIDS Patients
Clinigen Hlthcare · 1 drug in CMV Retinitis in AIDS Patients
Gilead Sciences · 1 drug in CMV Retinitis in AIDS Patients
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in CMV Retinitis in AIDS Patients
Roche Palo · 1 drug in CMV Retinitis in AIDS Patients

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in CMV Retinitis in AIDS Patients:

Cite this brief

Drug Landscape (2026). CMV Retinitis in AIDS Patients — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cmv-retinitis-in-aids-patients. Accessed 2026-06-10.

CMV Retinitis in AIDS Patients full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing